Novo Nordisk AS (NVO)
101.74
-3.58
(-3.40%)
USD |
NYSE |
Nov 15, 16:00
102.00
+0.26
(+0.26%)
After-Hours: 20:00
Novo Nordisk Research and Development Expense (TTM): 6.495B for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 6.495B |
| June 30, 2024 | 6.284B |
| March 31, 2024 | 4.992B |
| December 31, 2023 | 4.708B |
| September 30, 2023 | 4.310B |
| June 30, 2023 | 3.886B |
| March 31, 2023 | 3.578B |
| December 31, 2022 | 3.393B |
| September 30, 2022 | 3.148B |
| June 30, 2022 | 3.059B |
| March 31, 2022 | 2.965B |
| December 31, 2021 | 2.819B |
| September 30, 2021 | 2.671B |
| June 30, 2021 | 2.611B |
| March 31, 2021 | 2.458B |
| December 31, 2020 | 2.376B |
| September 30, 2020 | 2.308B |
| June 30, 2020 | 2.230B |
| March 31, 2020 | 2.279B |
| December 31, 2019 | 2.129B |
| September 30, 2019 | 2.174B |
| June 30, 2019 | 2.206B |
| March 31, 2019 | 2.199B |
| December 31, 2018 | 2.339B |
| September 30, 2018 | 2.274B |
| Date | Value |
|---|---|
| June 30, 2018 | 2.232B |
| March 31, 2018 | 2.209B |
| December 31, 2017 | 2.132B |
| September 30, 2017 | 2.150B |
| June 30, 2017 | 2.143B |
| March 31, 2017 | 2.144B |
| December 31, 2016 | 2.161B |
| September 30, 2016 | 2.104B |
| June 30, 2016 | 2.076B |
| March 31, 2016 | 2.019B |
| December 31, 2015 | 2.023B |
| September 30, 2015 | 2.080B |
| June 30, 2015 | 2.240B |
| March 31, 2015 | 2.356B |
| December 31, 2014 | 2.445B |
| September 30, 2014 | 2.447B |
| June 30, 2014 | 2.294B |
| March 31, 2014 | 2.205B |
| December 31, 2013 | 2.093B |
| September 30, 2013 | 2.001B |
| June 30, 2013 | 1.943B |
| March 31, 2013 | 1.910B |
| December 31, 2012 | 1.882B |
| September 30, 2012 | 1.822B |
| June 30, 2012 | 1.812B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
2.129B
Minimum
Dec 2019
6.495B
Maximum
Sep 2024
3.435B
Average
3.012B
Median
Research and Development Expense (TTM) Benchmarks
| Ascendis Pharma AS | 385.87M |
| Amgen Inc | 5.774B |
| AstraZeneca PLC | 11.98B |
| Grifols SA | 412.09M |
| Viking Therapeutics Inc | 91.16M |